Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Phase 2

Recruiting

Conditions: Acute Promyelocytic Leukemia With PML-RARA

Interventions: Drug: Arsenic Trioxide
Drug: Gemtuzumab Ozogamicin
Other: Laboratory Biomarker Analysis
Drug: Tretinoin

First Posted Date: 2011-08-04

Last Posted Date: 2025-01-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 151

Registration Number: NCT01409161

Locations: 🇺🇸
MD Anderson Regional Care Center-Bay Area, Nassau Bay, Texas, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
MD Anderson Regional Care Center-Katy, Houston, Texas, United States

and more 2 locations

IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma

Phase 1

Withdrawn

Conditions: Melanoma

Interventions: Drug: Ipilimumab
Drug: Interferon
Drug: Interleukin-2 (Aldesleukin)

First Posted Date: 2011-08-04

Last Posted Date: 2012-01-26

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01409187

Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Interferon-2A
Drug: Adriamycin
Drug: Bleomycin
Drug: Velban
Drug: Dacarbazine

First Posted Date: 2011-07-28

Last Posted Date: 2013-02-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 35

Registration Number: NCT01404936

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: BKM120

First Posted Date: 2011-07-18

Last Posted Date: 2016-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 16

Registration Number: NCT01396499

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Pegasys in Patients With Chronic Myeloid Leukemia (CML)

Phase 2

Terminated

Conditions: Leukemia

Interventions: Drug: PEG-IFNá-2a

First Posted Date: 2011-07-12

Last Posted Date: 2015-05-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT01392170

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

Phase 2

Completed

Conditions: Kidney Cancer

Interventions: Drug: Temsirolimus
Drug: Pazopanib
Behavioral: Quality of Life Assessment
Drug: Benadryl

First Posted Date: 2011-07-12

Last Posted Date: 2021-09-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 69

Registration Number: NCT01392183

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Phase II Evaluation of Exhaled Nitric Oxide (NO)

Completed

Conditions: Lung Cancer

Interventions: Procedure: Nitric oxide breath test
Behavioral: Questionnaires

First Posted Date: 2011-07-12

Last Posted Date: 2013-04-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 36

Registration Number: NCT01392144

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

Phase 2

Completed

Conditions: Chronic Myelogenous Leukemia
Leukemia

Interventions: Drug: Fludarabine
Drug: Busulfan
Drug: Interleukin-2
Drug: Anti-Thymocyte Globulin
Procedure: Allogeneic related Stem Cell Transplant
Drug: Tacrolimus
Drug: Methotrexate
Drug: G-CSF

First Posted Date: 2011-07-11

Last Posted Date: 2016-02-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT01390402

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

End of Life Treatment Preferences of Latino Medicare Beneficiaries With Cancer

Conditions: Advanced Cancers

Interventions: Behavioral: Telephone Survey

First Posted Date: 2011-07-08

Last Posted Date: 2019-07-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 230

Registration Number: NCT01389830

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Device: Visica 2™ Treatment System
Procedure: Cryoablation
Procedure: Surgical Resection

First Posted Date: 2011-07-07

Last Posted Date: 2018-07-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT01388777

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy